144 related articles for article (PubMed ID: 1440852)
1. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody.
Anasetti C; Martin PJ; Storb R; Appelbaum FR; Beatty PG; Davis J; Doney K; Hill HF; Stewart P; Sullivan KM
Transplantation; 1992 Nov; 54(5):844-51. PubMed ID: 1440852
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies.
Martin PJ; Hansen JA; Anasetti C; Zutter M; Durnam D; Storb R; Thomas ED
Am J Kidney Dis; 1988 Feb; 11(2):149-52. PubMed ID: 3277406
[TBL] [Abstract][Full Text] [Related]
3. Antilymphocytic antibodies and marrow transplantation. XII. Suppression of graft-versus-host disease by T-cell-modulating and depleting antimouse CD3 antibody is most effective when preinjected in the marrow recipient.
Mysliwietz J; Thierfelder S
Blood; 1992 Nov; 80(10):2661-7. PubMed ID: 1358260
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor.
Anasetti C; Hansen JA; Waldmann TA; Appelbaum FR; Davis J; Deeg HJ; Doney K; Martin PJ; Nash R; Storb R
Blood; 1994 Aug; 84(4):1320-7. PubMed ID: 8049447
[TBL] [Abstract][Full Text] [Related]
5. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease.
Anasetti C; Martin PJ; Hansen JA; Appelbaum FR; Beatty PG; Doney K; Harkonen S; Jackson A; Reichert T; Stewart P
Transplantation; 1990 Jul; 50(1):49-54. PubMed ID: 2368150
[TBL] [Abstract][Full Text] [Related]
6. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
[TBL] [Abstract][Full Text] [Related]
7. Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease.
Remlinger K; Martin PJ; Hansen JA; Doney KC; Smith A; Deeg HJ; Sullivan K; Storb R; Thomas ED
Hum Immunol; 1984 Jan; 9(1):21-35. PubMed ID: 6198309
[TBL] [Abstract][Full Text] [Related]
8. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
Blazar BR; Taylor PA; Vallera DA
J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
[TBL] [Abstract][Full Text] [Related]
10. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor.
Vallera DA; Panoskaltsis-Mortari A; Jost C; Ramakrishnan S; Eide CR; Kreitman RJ; Nicholls PJ; Pennell C; Blazar BR
Blood; 1996 Sep; 88(6):2342-53. PubMed ID: 8822957
[TBL] [Abstract][Full Text] [Related]
11. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
[TBL] [Abstract][Full Text] [Related]
12. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
Carpenter PA; Appelbaum FR; Corey L; Deeg HJ; Doney K; Gooley T; Krueger J; Martin P; Pavlovic S; Sanders J; Slattery J; Levitt D; Storb R; Woolfrey A; Anasetti C
Blood; 2002 Apr; 99(8):2712-9. PubMed ID: 11929757
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors.
Norman DJ; Vincenti F; de Mattos AM; Barry JM; Levitt DJ; Wedel NI; Maia M; Light SE
Transplantation; 2000 Dec; 70(12):1707-12. PubMed ID: 11152101
[TBL] [Abstract][Full Text] [Related]
14. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation.
Filipovich AH; Krawczak CL; Kersey JH; McGlave P; Ramsay NK; Goldman A; Goldstein G
Br J Haematol; 1985 May; 60(1):143-52. PubMed ID: 3890926
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.
Borrione P; Montacchini L; Beggiato E; Pileri A; Bianchi A; Massaia M
Leuk Lymphoma; 1996 Apr; 21(3-4):325-30. PubMed ID: 8726415
[TBL] [Abstract][Full Text] [Related]
17. Donor CD8+ T cells mediate graft-versus-leukemia activity without clinical signs of graft-versus-host disease in recipients conditioned with anti-CD3 monoclonal antibody.
Zhang C; Lou J; Li N; Todorov I; Lin CL; Cao YA; Contag CH; Kandeel F; Forman S; Zeng D
J Immunol; 2007 Jan; 178(2):838-50. PubMed ID: 17202345
[TBL] [Abstract][Full Text] [Related]
18. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
[TBL] [Abstract][Full Text] [Related]
19. Initial treatment of acute graft-versus-host disease with a murine monoclonal antibody directed to the human alpha/beta T cell receptor.
Beelen DW; Grosse-Wilde H; Ryschka U; Quabeck K; Sayer HG; Graeven U; Schaefer UW
Cancer Immunol Immunother; 1991; 34(2):97-102. PubMed ID: 1836976
[TBL] [Abstract][Full Text] [Related]
20. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
van Oosterhout YV; van Emst L; Schattenberg AV; Tax WJ; Ruiter DJ; Spits H; Nagengast FM; Masereeuw R; Evers S; de Witte T; Preijers FW
Blood; 2000 Jun; 95(12):3693-701. PubMed ID: 10845899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
